<DOC>
	<DOCNO>NCT01159626</DOCNO>
	<brief_summary>This Phase 1 study first clinical trial Japanese subject . The study design evaluate single- multiple-dose pharmacokinetics , safety tolerability PF-03463275 oral control release formulation Japanese Western male subject .</brief_summary>
	<brief_title>Pharmacokinetics , Safety Tolerability Study PF-03463275 Healthy Male Japanese Western Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy male subject age 18 55 year . Body Mass Index ( BMI ) 17.5 30.5 kg/m2 , total body weight &gt; 50 kg ( 110 lb ) . Japanese subject must four Japanese grandparent born Japan . Subjects genotyped PM ( poor metabolizer ) , UM ( ultrarapid metabolizer ) , IM/EM EM/UM CYP2D6 status . Evidence history clinically significant hematological ( include anemia ) , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Phase1</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Healthy Male</keyword>
	<keyword>Japanese</keyword>
	<keyword>Schizophrenia</keyword>
</DOC>